DeLong Mark Jeffrey's most recent trade in Apellis Pharmaceuticals Inc was a trade of 82,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 11 Feb 2025 | 363 | 83,945 (0%) | 0% | 28.5 | 10,360 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 365 | 84,308 (0%) | 0% | 29.5 | 10,776 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 1,396 | 84,673 (0%) | 0% | 30.4 | 42,474 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 28,508 | 86,069 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 1,235 | 57,561 (0%) | 0% | 30.0 | 36,998 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 1,599 | 58,796 (0%) | 0% | 28.7 | 45,895 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 12 Aug 2024 | 5,201 | 60,395 (0%) | 0% | 13.9 | 72,034 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,201 | 14,799 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 56.90 per share. | 18 Mar 2024 | 9,913 | 54,693 (0%) | 0% | 56.9 | 564,050 | Common Stock |
| Apellis Pharmaceuticals Inc | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 67.77 per share. | 12 Feb 2024 | 597 | 64,606 (0%) | 0% | 67.8 | 40,457 | Common Stock |
| Apellis Pharmaceuticals Inc | DeLong Jeffrey Mark | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 29 Jan 2024 | 367 | 65,203 (0%) | 0% | 64.1 | 23,539 | Common Stock |
| Apellis Pharmaceuticals Inc | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 1,384 | 65,570 (0%) | 0% | 65.0 | 89,954 | Common Stock |
| Apellis Pharmaceuticals Inc | DeLong Mark Jeffrey | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 24,666 | 24,666 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | DeLong Mark Jeffrey | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 16,963 | 68,585 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 16 Jan 2024 | 1,631 | 66,954 (0%) | 0% | 66.8 | 108,965 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 7,489 | 7,489 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 5,280 | 51,782 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 441 | 51,341 (0%) | 0% | 58.5 | 25,799 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. | 10 Feb 2023 | 670 | 46,502 (0%) | 0% | 51.2 | 34,311 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 27 Jan 2023 | 367 | 47,172 (0%) | 0% | 52.8 | 19,367 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 1,149 | 47,539 (0%) | 0% | 52.0 | 59,805 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 30,845 | 30,845 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Chief Business & Strat Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 19,634 | 48,688 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.00 per share. | 20 Oct 2022 | 196 | 29,054 (0%) | 0% | 58 | 11,368 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 17 Aug 2022 | 5,000 | 34,250 (0%) | 0% | 15.5 | 77,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 69.50 per share. | 17 Aug 2022 | 5,000 | 29,250 (0%) | 0% | 69.5 | 347,500 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 67.00 per share. | 11 Aug 2022 | 5,000 | 29,250 (0%) | 0% | 67 | 335,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 11 Aug 2022 | 5,000 | 34,250 (0%) | 0% | 15.5 | 77,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 08 Aug 2022 | 5,000 | 34,250 (0%) | 0% | 15.5 | 77,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 5,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 64.50 per share. | 08 Aug 2022 | 5,000 | 29,250 (0%) | 0% | 64.5 | 322,500 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 04 Aug 2022 | 10,000 | 39,250 (0%) | 0% | 15.5 | 155,200 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2022 | 10,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 62.00 per share. | 04 Aug 2022 | 5,000 | 29,250 (0%) | 0% | 62 | 310,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 04 Aug 2022 | 5,000 | 34,250 (0%) | 0% | 59.5 | 297,500 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 57.00 per share. | 27 Jul 2022 | 5,000 | 29,250 (0%) | 0% | 57 | 285,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2022 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 27 Jul 2022 | 5,000 | 34,250 (0%) | 0% | 15.5 | 77,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 56.42 per share. | 19 Jul 2022 | 5,000 | 29,250 (0%) | 0% | 56.4 | 282,100 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2022 | 5,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 19 Jul 2022 | 5,000 | 34,250 (0%) | 0% | 15.5 | 77,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 16 Jun 2022 | 10,000 | 39,250 (0%) | 0% | 13.9 | 138,500 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 10,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 41.78 per share. | 16 Jun 2022 | 10,000 | 29,250 (0%) | 0% | 41.8 | 417,850 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 52.53 per share. | 20 Apr 2022 | 7,000 | 28,481 (0%) | 0% | 52.5 | 367,710 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 20 Apr 2022 | 7,000 | 35,481 (0%) | 0% | 15.5 | 108,640 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 7,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 6,952 | 6,952 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 4,901 | 28,481 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 271 | 23,580 (0%) | 0% | 47.1 | 12,770 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 434 | 20,530 (0%) | 0% | 38.6 | 16,748 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 19,735 | 19,735 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 13,913 | 24,285 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2021 | 882 | 10,372 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 21 Jul 2021 | 1,000 | 10,490 (0%) | 0% | 15.5 | 15,520 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 1,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 21 Jul 2021 | 1,000 | 9,490 (0%) | 0% | 65 | 65,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,000 | 43,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 62.30 per share. | 15 Jul 2021 | 1,000 | 9,490 (0%) | 0% | 62.3 | 62,300 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 15 Jul 2021 | 1,000 | 10,490 (0%) | 0% | 15.5 | 15,520 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.52 per share. | 18 May 2021 | 2,000 | 11,490 (0%) | 0% | 15.5 | 31,040 | Common Stock |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 2,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Mark Jeffrey DeLong | Senior Vice President | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 18 May 2021 | 2,000 | 9,490 (0%) | 0% | 55 | 110,000 | Common Stock |